Osimertinib is a targeted therapy, belonging to the third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors.Side effects r···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 175
Osimertinib, as a third-generation EGFR-TKI, has become a breakthrough drug in the treatment of non-small cell lung cancer (NSCLC) due to its highly e···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 170
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved osimertinib for first-line treatment of patient···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 159
On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to osimertinib for the treatment of patients with advan···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 171
Pralsetinib was approved for marketing by the U.S. Food and Drug Administration (FDA) in September 2020, and subsequently approved in several countrie···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 142
Pralsetinib is a potent, highly selective RET tyrosine kinase inhibitor developed by Blueprint Medicines, Inc. It is used to treat RET fusion-positive···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 149
Pralsetinib is a potent, highly selective RET tyrosine kinase inhibitor developed by Blueprint Medicines, Inc. It is used to treat RET fusion-positive···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 147
Pralsetinib is a receptor tyrosine kinase (RET) inhibitor. It was approved for marketing by the US FDA in 2020.Side effects requiring immediate medica···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 152
On August 9, 2023, the U.S. Food and Drug Administration (FDA) granted regular approval to pravlatinib (Gavreto, Genentech) for the treatment of adult···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 145
On September 4, 2020, Genentech, a Roche company, announced that the U.S. Food and Drug Administration (FDA) has approved pramintinib (Gavreto) for th···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 143
Pralsetinib, developed by Blueprint Medicines, is an oral, highly selective, and potent RET inhibitor.Common Dosages for Pralsetinib1. Adult Non-Small···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 156
Osimertinib is a targeted therapy for the treatment of certain types of non-small cell lung cancer. Currently, its price in China varies depending on ···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 167
Osimertinib is a targeted therapy for non-small cell lung cancer. Common side effects include skin reactions (rash, dryness), gastrointestinal discomf···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 165
The price of osimertinib varies depending on the dosage, region, and medical insurance policy, currently ranging from several thousand to tens of thou···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 175
The price of osimertinib varies depending on the dosage, region, and medical insurance policy, currently ranging from several thousand to tens of thou···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 168
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos